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Summary/Abstract 
Interrupted time-series (ITS) analysis is being increasingly used in epidemiology. 
Despite its growing popularity, there is a scarcity of guidance on power and sample 
size considerations within the ITS framework. Our aim here was to assess the statistical 
power to detect an intervention effect under various real life ITS scenarios. ITS 
datasets were created using Monte-Carlo simulations to generate cumulative 
incidence (outcome) values over time. We generated 1,000 datasets per scenario, 
varying the number of time points, average sample size per time point, average 
relative reduction post-intervention, location of intervention in the time-series and 
reduction mediated via a: (i) slope change and (ii) step change. Performance measures 
included power and % bias. We found that sample size per timepoint had a large 
impact on power. Even in scenarios with 12 pre-intervention and 12 post-intervention 
timepoints with moderate intervention effect sizes, most analyses were underpowered 
if the sample size per timepoint was low. We conclude that various factors need to be 
collectively considered to ensure adequate power for an ITS study. We have 
demonstrated a means of providing insight on underlying sample size requirements in 
ordinary least squares ITS analysis based on pre-specified parameters and have 
developed Stata code to estimate this. 
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INTRODUCTION 
 
Interrupted time-series (ITS) analysis is being increasingly used in epidemiology. (1-3) It 
is an accessible and intuitive method that can be straight-forward to implement and 
has considerable strengths (4). A common application is when population-level 
repeated measures of an outcome and/or exposure are available over time, both 
before and after some well-defined intervention such as a health policy change (1, 2, 5) 
or a naturally occurring event of interest. (6, 7)  
 
Despite the substantial growth in use of ITS methods, relatively little practical guidance 
has been developed in terms of methodological standards within the ITS framework, 
(1, 3) including a scarcity of guidance on required sample size. Sample size planning is 
often a key component of designing a study and should be conducted prior to analysis 
(8), although this is an aspect very often overlooked in ITS studies, with many being 
underpowered (9). 
 
Information on the power associated with various numbers of repeated measures of 
an outcome (i.e. timepoints) has been previously reported (10), with rules of thumb 
concerning the minimum number of pre- and post-intervention timepoints needed, 
such as three, (3) six, (11) eight, (12)  and 10. (9) However, researchers seeking to 
aggregate patient-level data into a population-level timeseries in order to conduct an 
ITS are confronted with the practical issue of considering a suitable underlying sample 
size of subjects/patients per aggregate timepoint (13). While longer time-series have 
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been shown to have more power than short time-series, it seems reasonable to 
propose that ITS analyses (even those with many timepoints) with only a small number 
of subjects per timepoint may contain so much noise as to render it improbable of 
detecting a true impact of an intervention under study. While the ITS method has 
many strengths, if a given analysis is not adequately powered it may lead to 
publication of weak and spurious findings (14, 15). 
 
Given this paucity of guidance on sample size calculation, our aim here was to use a 
simulation approach to estimate power in an ITS analysis case-study of repeated 
measures of cumulative incidence generated from routinely collected healthcare data. 
We aimed to quantify the power available in relation to the underlying sample size per 
timepoint, while varying a number of other key parameters of interest. Furthermore, 
we set out to make available Stata code to be readily usable by epidemiologists as a 
tool to generate estimates of required sample size for similar ITS applications.  
 
METHODS 
 
Study design 
We used Monte-Carlo simulations, the strengths of which have been well described 
previously (16, 17). Briefly, simulation studies involve generating data with known 
characteristics defined by pre-specified input parameter values. Consequently, 
because the truth regarding these characteristics is known, it is possible to empirically 
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evaluate the performance of a given statistical model when fitted to the simulated 
data (18, 19). 
 
Aims 
Our aim was to describe the power associated with the mean sample size per 
timepoint to detect a change in: (i) level and (ii) trend in an outcome (cumulative 
incidence) following a defined intervention in the ITS framework, using OLS regression. 
We considered a range of values for various other factors such as total number of 
timepoints, effect size and location of intervention in the time-series. We set out to 
apply the methods within the context of a specific case-study using a recent ITS 
analysis where we evaluated the impact of a UK NICE technology appraisal on the 
cumulative incidence of joint replacement within the Clinical Practice Research 
Datalink (CPRD). (20)  
 
ITS scenarios 
There are many factors within an ordinary least squares ITS framework that could 
conceivably influence the power to detect the impact of an intervention. Although the 
following is not an exhaustive list, we here describe the main factors that we 
investigated. 
 
1. Total number of timepoints in the time-series, N (figure 1A & 1B) 
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As described in the introduction, the ITS approach relies on repeated observations of 
an outcome event over time, usually at equally spaced intervals such as days, weeks, 
months, quarters, years, etc. We investigated nine values for total number of 
timepoints (N), ranging from 6 to 50. 
 
2. Number of subjects per timepoint, n (figure 1C & 1D) 
 
The sample size per timepoint will impact the accuracy of outcome estimates and 
hence the dispersion of a given time-series. It is therefore an important factor 
influencing the power to detect an ‘interruption’. We investigated 11 values for n, 
ranging from approximately 150 to 5700 patients per timepoint, which for our specific 
case-study corresponded to a mean number of outcome events per timepoint that 
ranged from 5 to 200 (supplementary file 1). 
 
3. Nature of intervention impact (figure 1A & 1B versus 1C & 1D) 
 
The impact of an intervention can be modelled as a ‘step’ change in the level of 
outcome and/or a ‘slope’ change in the trend of outcome. (4, 21) More complex 
realities can be incorporated such as multiple interventions, waning or delayed effects 
and non-linear responses. (2, 21) However, for the purposes of the current work we 
only considered intervention effects mediated through either: (i) a step change or (ii) a 
slope change 
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4. Effect size – i.e. magnitude of intervention impact 
 
One of the assumptions of ITS analysis is that the pre-intervention level and trend of 
outcome can be used to predict post-intervention counterfactual estimates, i.e. what 
outcomes would be expected in the post-intervention period had the intervention not 
occurred. (2, 21) The impact of intervention can then be expressed as the difference 
between the estimated counterfactual outcome value for a given post-intervention 
timepoint versus the estimated modelled outcome value for the same timepoint using 
the observed data. (22) In practice this has often been done for the mid-point of the 
post-intervention period in order to yield an average post-intervention change. (5, 20, 
23) We therefore used the magnitude of this average post-intervention change 
expressed as a relative % to express effect size, defined for mid-time-series 
interventions as the step or slope change resulting in a -15%, -34%, -50% and -75% 
reduction. 
 
5. Mean pre-intervention level and trend of outcome 
 
The absolute pre-intervention level of outcome is an important factor. For example, a 
relative 50% reduction of a common outcome should be easier to detect than a 
relative 50% reduction of a rare outcome. Furthermore, a pre-intervention trend in 
outcome may exist, which may also have an effect on power. We therefore considered 
two parameters: the mean pre-intervention outcome value (defined using the pre-
intervention mid-point) in conjunction with a pre-intervention trend parameter. In 
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main analyses we here only explored scenarios (based on our prior CPRD study (20)) 
where mean pre-intervention cumulative incidence was 3.5% and where there was 
either: (i) no pre-intervention trend (for step change scenarios) or (ii) an upward trend 
(for slope change scenarios) (figure 1). We scaled trend parameters according to N so 
that absolute pre-intervention values were constant across all mid-time-series 
intervention scenarios. Exact parameter values for these are provided in 
supplementary file 1. 
 
6. Location of intervention in time-series 
 
Related to N, location of intervention in the time-series may also have an impact on 
power as this will affect the balance in number of pre-intervention and post-
intervention timepoints to be modelled. Locations investigated were at: one-third, 
mid-way and two-thirds from the beginning of the time-series. For trend change 
scenarios in our case-study, we used the same pre-intervention and post-intervention 
trends when investigating early/late interventions as per the corresponding mid-way 
intervention setting within each N scenario (supplementary file 1).  
 
Data Generating Process 
Data were generated in Stata v15.2, the general principles of which have been 
described elsewhere (24). Empty time-series datasets were created of length N (total 
number of timepoints). Three ITS variables were inserted: timepoint identifier 
(integer), post-intervention indicator (binary) and post-intervention timepoint 
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identifier (integer) (21). The timepoint identifier was created first, then used in 
combination with the ‘location of intervention’ parameter to generate the other two 
ITS variables. The underlying sample size for each timepoint (nt) was simulated from a 
normal distribution with mean n (a key parameter of interest; 11 values investigated) 
and standard deviation of n/3. The number of outcome events occurring per timepoint 
were drawn as a binomial random variate (nt, pt), where nt represents the sample size 
and pt the probability of outcome. pt was a linear function defined using the ITS 
variables in combination with other scenario-specific parameter values (equation 
included in supplementary file 1). The number of events per timepoint and nt were 
used to derive the cumulative incidence time-series. A total of 1,000 Monte-Carlo 
repetitions were carried out for each unique scenario. 
 
Methods of analysis 
A segmented linear regression model was fitted to each created dataset. This took the 
form of model (1) for step change scenarios and model (2) for slope change scenarios: 
 
(1) Yt=β0 + β1*timepointt + β2*intervention_indicatort + et. 
(2) Yt=β0 + β1*timepointt + β3*post_intervention_timepointt + et. 
 
Here, Yt is the value of outcome at timepoint t. β0 estimates the level of the outcome 
just before the beginning of the time-series. β1 estimates the pre-intervention trend, 
β2 the change in level between the time point immediately before vs. after the 
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intervention and β3 the change in trend occurring immediately after the intervention. 
et is the error term. 
 
Estimands 
The target of inference was change in outcome following an intervention, specifically 
testing the null hypothesis of no change (i.e. β2=zero [model 1] or β3=zero [model 2]). 
The outcome at each timepoint was a proportion, which in our case-study was the 5-
year cumulative incidence of joint replacement within rheumatoid arthritis patients. 
(20) 
 
Performance 
The coefficients, standard error and p-values from these models were stored and the 
empirical power to reject the null hypothesis of no post-intervention change was 
calculated as the proportion of simulations where the P-value for the intervention 
variable coefficient (step/slope change) was <0.05. (19, 24, 25) This was represented 
graphically as contour plots across scenarios according to N and n. We truncated the Y 
axis (depicting sample size) of main graphs although the full axis was used for graphs in 
the supplementary material. For convenience of comparison, additional presentation 
was made for power according to different effect size and location scenarios while 
keeping N constant (N=28). Also calculated for midway step and slope change 
scenarios (while keeping N constant) was the percentage bias (19) of the regression 
coefficients, defined as:  
 
average estimate across simulations – true parameter value  
         true parameter value 
% Bias = *100 
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Sensitivity analysis 
In order to explore the impact of pre-intervention level of outcome, we repeated main 
analyses investigating power for slope and step changes while keeping N constant 
(N=28) but varying pre-intervention level from 3.5% to (i) 8% and (ii) 20%. These main 
analyses were also repeated where the intervention impact was in the form of an 
increase in outcome rather than reduction. 
 
Stata programme 
Although we based the present analyses on a case-study exploring a range of 
parameter values adapted from our prior CPRD study as specified above, we also 
developed a Stata programme (supplementary file 6) with associated documentation 
(supplementary file 5) in order to provide a ready-to-use means for assessing power 
associated with any valid list of (nine) input parameter values, as described in the 
supplementary file 5. 
 
RESULTS 
 
Results from our case-study are presented below describing the impact of N and n on 
power within several ITS scenarios. Although the main results pertain to a setting 
where the mean pre-intervention level of outcome for mid-time-series interventions 
  12 
was 3.5%, the Stata programme developed can be used to explore alternative input 
parameter values (supplementary file 6). 
 
Slope change 
As expected, power increased as N and/or n increased (figure 2A) and as effect sizes 
became larger (figure 3A). Results for different N and n combinations for each effect 
size investigated are provided in supplementary file 2. These indicated that nearly all 
mid-time-series intervention scenarios with a large effect size (-75%) had at least 80% 
power when there were >24 total timepoints, even when there was a very small 
sample size per timepoint (~150 subjects, corresponding here to only 5 outcome 
events per timepoint). However, when the effect size was small (-15%) then to achieve 
80% power an analysis had to either contain a large N or very large n (supplementary 
file 2). While keeping other factors constant (effect size =-34% and N=28), power was 
greater in scenarios with mid-time-series interventions, with comparably less power in 
scenarios with earlier/later interventions (figure 4A). The % bias in model coefficients 
was small and this trended towards zero as sample size increased (Figure 5) 
 
Step change 
 
Similar to slope change scenarios, power increased as N and n became larger (figure 
2B) or as the effect size was larger (figure 3B). Generally, there was less power in step 
change scenarios than in corresponding slope change scenarios (figure 2A versus 2B), 
with nearly all mid-time-series intervention scenarios being inadequately powered 
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when the effect-size was only -15% (figure 3B, supplementary file 3). Even when effect 
sizes were large and number of timepoints was moderate (14 pre-intervention and 14 
post- intervention timepoints), analyses were underpowered if sample size per 
timepoint was low (figure 3B, supplementary figure 3). Interestingly, little difference 
was found in power following an early or late intervention as compared to when the 
intervention occurred mid-way through (figure 4). The % bias in model coefficients was 
small and this trended towards zero as sample size increased (Figure 5) 
 
DISCUSSION 
 
Main findings 
 
This study demonstrates that simple rules regarding the number of timepoints are not 
adequate by themselves to denote an ITS analysis as sufficiently powered. Other 
factors such as the sample size per timepoint, expected effect size, location of 
intervention in the time-series and pre-intervention trends need to be considered. For 
example, in our case-study where mean pre-intervention level of outcome was 3.5%, 
to achieve 80% power to detect a relative 34% post-intervention step change 
reduction, with 14 pre- and 14 post-intervention timepoints, one needed over 1,000 
subjects per timepoint (i.e.  >28,000 total subjects), which may or may not be realistic 
for a given study. However, three pre- and post-intervention timepoints were equally 
sufficient to achieve 80% power in relatively rare situations of large intervention effect 
sizes combined with very large sample sizes per timepoint (supplementary files 2-4). 
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These results underline the importance of robust pre-study sample size planning. 
Estimates arising from scenarios with a very small n were only very slightly biased, 
which disappeared as n increased (figure 3). 
 
That power increases as N increases is an expected finding and has previously been 
shown for fixed ratios of effect size to the standard deviation of the timeseries (10, 
26). However, we’ve here addressed the previously unknown trade-off between N and 
n. This is an important consideration and a helpful development. Firstly, because the 
standard deviation of a given number of population-level timepoints may likely be 
difficult for applied researchers to estimate in advance of a proposed ITS study. 
Secondly, because exploring this trade-off between N and n informs to what extent it 
may be beneficial (in terms of power) when generating an aggregate ITS dataset to 
sacrifice sample size per timepoint in order to increase the number of timepoints (or 
vice-versa). It allows a combination of N and n to be selected to optimise power. 
Although the exact nuances of this unique trade-off were scenario specific, in most 
cases only very little gain in power was achieved when a time-series was lengthened at 
the expense of timepoint sample size, although gains were more noticeable where a 
very short time-series was lengthened. 
 
To our knowledge, a differential power according to whether an intervention impact is 
mediated via a slope or step change has not previously been investigated. We found 
power was greater in slope change scenarios, a likely explanation being that our effect 
size was the average difference between post-intervention values and counterfactuals, 
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which in the case of slope change scenarios continued to increase as per the pre-
intervention slope and therefore made detection of a change more probable. 
 
Within scenarios with a slope change we found power to be greater in settings with a 
balanced number of pre-intervention and post-intervention timepoints (as opposed to 
earlier/later interventions), while the location of the intervention had little impact on 
power to detect step changes and was even marginally greater when the intervention 
occurred early. Although this was unexpected, it is not without some support from 
previous work (10).  
 
Limitations 
Our study is subject to various limitations. Each timepoint was a cumulative incidence, 
and given that individual subjects/patients could only be included in a single timepoint 
we treated timepoints to be independent. As such we’ve not explored what impact 
autocorrelation may have on estimates, although this remains a subject for further 
investigation. Despite the availability of ITS approaches that explicitly model 
autocorrelation, such as autoregressive integrated moving average (ARIMA) models 
(27), it would seem that where the assumptions of OLS regression are met then this is 
preferable for epidemiological studies where the goal is likely to be causal inference 
rather than future prediction. Indeed, while autocorrelation needs to be addressed 
where present, it has been noted that in epidemiological studies it can often be 
accounted for by controlling for other variables (2), and interestingly of a recent review 
of over 200 drug utilization studies implementing ITS analysis, 50% were found to use 
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segmented linear regression (1). Specification of ARIMA models are frequently cited to 
require a minimum of 50 timepoints (28), with >100 being preferable (27), yet it is 
common to have less than this minimum available in epidemiology contexts using 
routinely collected data (10, 21, 23, 29). For these reasons, our focus here was on 
‘short’ time-series where we’ve considered 50 timepoints as a maximum and used 
Durbin Watson statistics to confirm first-order autocorrelation was not present. 
Previous work has investigated the relationship between the number of timepoints 
and power in the presence of autocorrelation (10, 30), where positive autocorrelation 
has been shown to reduce power and negative autocorrelation to increase power (10). 
Similarly, we’ve not considered seasonality nor situations where there may be a delay 
or waning intervention effect.  
 
Another limitation is that our definition of effect size as the difference between post-
intervention timepoints and counterfactual timepoints (i.e. what would have been 
observed had pre-intervention level/slope continued uninterrupted) involves 
extrapolation and therefore uncertainty. While this is often done in practice, with 
uncertainty of model estimates expressed using confidence intervals, (22) there is still 
the assumption that pre-intervention trends would have continued unchanged.  
 
We’ve also only investigated scenarios where the repeated outcome measure is a 
cumulative incidence (i.e. a proportion). This is a very common epidemiological 
measure, but incorporating other common measures such as person-year rates, means 
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(for example length of hospital stay or drug doses prescribed) and frequencies is a 
logical next step and remains the subject for imminent further investigation.  
 
Strengths 
 
The disentangling of N and n is a key strength and novel aspect of the current study, as 
is the separate consideration of post-intervention step and slope changes. The 
development and inclusion of a Stata programme is an important feature of the 
investigation, facilitating researchers to estimate sample size requirements for future 
ITS studies and thereby promoting the avoidance of carrying out underpowered 
analyses. We are currently working on using this tool as the basis for an online 
calculator. It is also worth mentioning that we based the parameter values for our 
case-study on a “real world” clinical scenario (20) in order to increase the applicability 
of the findings, rather than starting from arbitrary parameter values. 
 
Conclusion 
 
Multiple factors influence the power of OLS ITS analysis and these should be 
collectively taken into account when considering the feasibility of a proposed ITS 
study. We have demonstrated how a simulation approach can be used to estimate the 
power available within specific ITS scenarios and have developed Stata code to 
facilitate pre-analysis sample size planning of future ITS studies within similar 
applications. 
  18 
 
Funding 
 
This project was partially supported by Oxford NIHR Biomedical Research Unit. Andrew 
Judge was partially supported by the NIHR Biomedical Research Centre at the 
University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The 
views expressed in this publication are those of the authors and not necessarily those 
of the NHS, the National Institute for Health Research or the Department of Health. 
 
Competing interests 
 
SH, SA and KB have no conflicts of interest. AJ has received consultancy fees from 
Freshfields Bruckhaus Deringer, and is a member of the Data Safety and Monitoring 
Board (which involved receipt of fees) from Anthera Pharmaceuticals, INC. outside the 
submitted work. DPAs research group has received unrestricted research grants from 
Servier Laboratoires, AMGEN and UCB Pharma. 
 
Author contributions:  
 
Study design: SH, DPA, AJ; Data simulation: SH, SA, KB; Data analysis: SH, KB, SA; 
Drafting manuscript: SH; Correcting and/or approving final manuscript: All authors 
 
 
  19 
 
 
References 
 
1. Jandoc R, Burden AM, Mamdani M, Levesque LE, Cadarette SM. Interrupted 
time series analysis in drug utilization research is increasing: systematic review and 
recommendations. J Clin Epidemiol. 2015;68(8):950-6. 
2. Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for 
the evaluation of public health interventions: a tutorial. International journal of 
epidemiology. 2016. 
3. Ewusie JE, Blondal E, Soobiah C, Beyene J, Thabane L, Straus SE, et al. Methods, 
applications, interpretations and challenges of interrupted time series (ITS) data: 
protocol for a scoping review. BMJ Open. 2017;7(6):e016018. 
4. Kontopantelis E, Doran T, Springate DA, Buchan I, Reeves D. Regression based 
quasi-experimental approach when randomisation is not an option: interrupted time 
series analysis. Bmj. 2015;350:h2750. 
5. Hawton K, Bergen H, Simkin S, Dodd S, Pocock P, Bernal W, et al. Long term 
effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant 
activity in England and Wales: interrupted time series analyses. Bmj. 2013;346:f403. 
6. Laliotis I, Ioannidis JPA, Stavropoulou C. Total and cause-specific mortality 
before and after the onset of the Greek economic crisis: an interrupted time-series 
analysis. Lancet Public Health. 2016;1(2):e56-e65. 
7. Craig P, Cooper C, Gunnell D, Haw S, Lawson K, Macintyre S, et al. Using natural 
experiments to evaluate population health interventions: new Medical Research 
Council guidance. J Epidemiol Community Health. 2012;66(12):1182-6. 
8. Lenth RV. Some practical guidelines for effective sample size determination. 
Am Stat. 2001;55(3):187-93. 
9. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. Interrupted time 
series designs in health technology assessment: lessons from two systematic reviews 
of behavior change strategies. Int J Technol Assess Health Care. 2003;19(4):613-23. 
10. Zhang F, Wagner AK, Ross-Degnan D. Simulation-based power calculation for 
designing interrupted time series analyses of health policy interventions. J Clin 
Epidemiol. 2011;64(11):1252-61. 
11. Fretheim A, Zhang F, Ross-Degnan D, Oxman AD, Cheyne H, Foy R, et al. A 
reanalysis of cluster randomized trials showed interrupted time-series studies were 
valuable in health system evaluation. J Clin Epidemiol. 2015;68(3):324-33. 
12. Penfold RB, Zhang F. Use of Interrupted Time Series Analysis in Evaluating 
Health Care Quality Improvements. Acad Pediatr. 2013;13(6):S38-S44. 
13. Cordtz RL, Hawley S, Prieto-Alhambra D, Hojgaard P, Zobbe K, Overgaard S, et 
al. Incidence of hip and knee replacement in patients with rheumatoid arthritis 
following the introduction of biological DMARDs: an interrupted time-series analysis 
using nationwide Danish healthcare registers. Ann Rheum Dis. 2018;77(5):684-9. 
  20 
14. Van Calster B, Steyerberg EW, Collins GS, Smits T. Consequences of relying on 
statistical significance: Some illustrations. Eur J Clin Invest. 2018;48(5):e12912. 
15. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power 
failure: why small sample size undermines the reliability of neuroscience. Nat Rev 
Neurosci. 2013;14(5):365-76. 
16. Chang M. Monte Carlo Simulation for the Pharmaceutical Industry: Concepts, 
Algorithms, and Case Studies: CRC Press; 2010. 
17. Ripley BD. Stochastic Simulation. New York, United States: John Wiley and Sons 
Ltd; 2006. 
18. Morris T, White I, Crowther M. Using simulation studies to evaluate statistical 
methods. Tutorial in Biostatistics. 2017. 
19. Burton A, Altman DG, Royston P, Holder RL. The design of simulation studies in 
medical statistics. Statistics in medicine. 2006;25(24):4279-92. 
20. Hawley S, Cordtz R, Lene D, Edwards CJ, Arden NK, Delmestri A, et al. 
Association between NICE guidance on biologic therapies with rates of hip and knee 
replacement among rheumatoid arthritis patients in England and Wales: An 
interrupted time-series analysis.  American College of Rheumatology; Washington DC: 
Arthritis Rheumatol.; 2016. 
21. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression 
analysis of interrupted time series studies in medication use research. J Clin Pharm 
Ther. 2002;27(4):299-309. 
22. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating 
confidence intervals in interrupted time series analyses of health interventions. J Clin 
Epidemiol. 2009;62(2):143-8. 
23. Hawton K, Bergen H, Simkin S, Brock A, Griffiths C, Romeri E, et al. Effect of 
withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England 
and Wales: time series analysis. Bmj. 2009;338:b2270. 
24. Feiveson AH. Power by simulation. The Stata Journal. 2002;2(2):107-24. 
25. Sayers A, Crowther MJ, Judge A, Whitehouse MR, Blom AW. Determining the 
sample size required to establish whether a medical device is non-inferior to an 
external benchmark. BMJ Open. 2017;7(8):e015397. 
26. McLeod AI, Vingilis ER. Power computations in time series analyses for traffic 
safety interventions. Accid Anal Prev. 2008;40(3):1244-8. 
27. Box GEPJ, G.M.; Reinsel, G.C.; Ljung, G.M. Time Series Analysis: Forecasting and 
Control. 5th ed: WILEY; 2015 29/06/2015. 
28. Chatfield C. The Analysis of Time Series: an introduction. Chatfield CT, M.; 
Zidek, J., editor. Taylor & Francis e-Library: CHAPMAN & HALL/CRC; 2009. 
29. Hawley S, Leal J, Delmestri A, Prieto-Alhambra D, Arden NK, Cooper C, et al. 
Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture 
Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-
Series Analysis. Journal of bone and mineral research : the official journal of the 
American Society for Bone and Mineral Research. 2016;31(11):2008-15. 
30. McLeod AI, Vingilis ER. Power computations for intervention analysis. 
Technometrics. 2005;47(2):174-81. 
 
  21 
 
